Skip to main content

Carmen Espejo Ruiz

I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Carmen Espejo Ruiz

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.

I obtained my degree in Biology from the University of Barcelona in 1998. I did my doctoral thesis at the Clinical Neuroimmunology Unit of the Hospital Universitari Vall d'Hebron, in which I studied the role of metallothioneins in the pathogenesis of multiple sclerosis, obtaining my PhD in Biology from the University of Barcelona in 2005. In 2008, I got a Miguel Servet contract that allowed me to establish myself as principal investigator of the Clinical Neuroimmunology group – Multiple Sclerosis Centre of Catalonia. Currently, I am a senior researcher at the Vall d'Hebron Research Institute and develop my scientific activity in the Clinical Neuroimmunology group - Center d'Esclerosi Múltiple de Catalunya.
My main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim of developing new therapeutic strategies. I am currently focused on the role of immunosenescence in the pathogenesis of multiple sclerosis and the therapeutic potential of different senolytic drugs. I am also studying how the modification of the gut microbiota, through the administration of probiotics, could constitute a therapeutic tool in multiple sclerosis. Finally, I am carrying out a project that aims to induce immune tolerance, through the use of nanomedicine, with the aim of slowing down the autoimmune response in multiple sclerosis. I have more than 25 years of experience in animal models of multiple sclerosis and in the study of the immune response.
At the Vall d'Hebron Research Institute, I am a member (since 2003) and the president (since 2006) of the Animal Experimentation Ethics Committee. I am also part of the Biosafety Committee (since 2015) and the Research Integrity Committee (since 2020).
I have participated, as main or collaborating author, in 70 publications indexed in peer review journals. I have supervised eight doctoral theses and eight master's final projects. In addition, I participated as a teacher in various training activities, including the Master of Advanced Immunology at the Autonomous University of Barcelona and the University of Barcelona.

Projects

¿Podemos retrasar o frenar la neurodgeneración en la esclerosis múltiple?

IP: Carmen Espejo Ruiz
Collaborators: -
Funding agency: Fundación Caja Navarra
Funding: 2861.07
Reference: CAN-2010-16365
Duration: 01/01/2011 - 31/12/2011

Función de las semaforinas 3A y 7A, moléculas de guía axonal, en la neurorregeneración y la regulación de la respuesta inmunitaria en la encefalomielitis autoinmune experimental

IP: Carmen Espejo Ruiz
Collaborators: Herena Eixarch Ahufinger, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 173030
Reference: PI09/01180
Duration: 01/01/2010 - 30/06/2014

Unitat de Neuroimmunologia Clínica (UNiC)

IP: Xavier Montalban Gairín
Collaborators: Susana Otero Romero, Carlos Nos Llopis, Sunny Malhotra Sareen, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Silvia Soler García, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo, Georgina Arrambide García
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 793
Duration: 01/01/2010 - 30/04/2014

United Europeans for the development of Pharmacogenomics in Multiple Sclerosis (UEPHA-MS) Grant Agreement Nº 212877

IP: Manuel Comabella Lopez
Collaborators: Sunny Malhotra Sareen, Jordi Rio Izquierdo, Xavier Montalban Gairín, Carmen Espejo Ruiz
Funding agency: EUROPEAN COMMISSION
Funding: 185749.7
Reference: UEPHA-MS_FP7PEOPLE_ITN2008
Duration: 15/09/2008 - 14/09/2012

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Basilio Rodriguez  Diez

Basilio Rodriguez Diez

Senior researcher
Systemic Diseases
Read more
Laura Doménech Moral

Laura Doménech Moral

Main researcher
Basic, Translational and Clinical Pharmacy Research
Read more
José Raul Herance Camacho

José Raul Herance Camacho

Head of group
Molecular Medical Imaging
Read more
Jesús  Cirbián Franqueira

Jesús Cirbián Franqueira

Predoctoral researcher
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.